AzTrials
AzTrials

Neuromuscular DiseasesNCT03867721

Patient Preference for Mouthpiece Ventilation

A study testing Ventilator in people with Neuromuscular Diseases, run by Revalidatieziekenhuis InkendaaI at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

BACKGROUND: Patients with severe neuromuscular disorders (NMDs) are likely to develop progressive respiratory insufficiency, leading to noninvasive ventilation during the night and, later, during night and day. Ventilation via a mouthpiece (MPV) is an elegant option to offer daytime ventilation. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Neuromuscular Diseases
What is being tested?
Ventilator
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteBelgium
Study dates
1 Jan 2015to 30 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • All individuals affected by NMDs attending our Centre for Home Mechanical Ventilation between January 2015 and December 2018 who required daytime MPV as an extension of nocturnal NIV

Who cannot join

  • Patients with no need for daytime ventilation
  • patients with ineffective NIV during sleep as assessed by the measurement of TcCO2>49mmHg (S)
  • patients with uncontrollable oral leaks with MPV or episode of acute respiratory infection during the trials

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Michel Toussaint

    Vlezenbeek, 1602

Other trials in Belgium

About this study

Official title: The Preference of Neuromuscular Patients Regarding Available Equipment for Daytime Mouthpiece Ventilation: a Randomized Cross-over Study

BACKGROUND:

Patients with severe neuromuscular disorders (NMDs) are likely to develop progressive respiratory insufficiency, leading to noninvasive ventilation during the night and, later, during night and day. Ventilation via a mouthpiece (MPV) is an elegant option to offer daytime ventilation. The patient preference regarding the ideal material for daytime MPV is unclear.

Read more

OBJECTIVES:

The purpose of this study was to determine which ventilator, tubing support and mouthpiece was most effective and preferred by patients with NMDs.

METHODS:

Two separate MPV equipment sets were compared in 20 patients with NMDs in a randomized cross-over study. The first set consisted in a non-dedicated ventilator for MPV (PB560, Covidien) combined with a customized tubing support on the shoulders and a plastic angled mouthpiece. The second set included an MPV-dedicated ventilator (Trilogy 100, Philips Respironics) without back-up rate and kiss trigger combined with a commercially available tubing support and a silicone straw mouthpiece. The Borg dyspnea score, the free time without noninvasive ventilation, the transcutaneous oxygen saturation (SpO2) and carbon dioxide tension (TcCO2) were recorded without and with MPV. A 17-items list assessing the patient perception about MPV sets was completed.

Read the detailed description

Materials and Methods

Aims

The primary aim of the study was to compare blood gas measurements, dyspnea score and general perception between the two sets for MPV. The second aim of the study was to determine the preference of patients on MPV equipment according to their free time. We also aimed at collecting individual comments of patients regarding their experience with the two ventilators, arm supports and mouthpieces.

Patients

All individuals affected by NMDs attending our Centre for Home Mechanical Ventilation between 2015 and 2018 who required daytime MPV as an extension of nocturnal NIV were considered for study inclusion. Our criterion for implementing daytime ventilation was the combined presence of increasing dyspnea and increasing workload on inspiratory muscles during the daytime (C) or, ultimately, daytime hypercapnia in the evening when patients lay in bed before starting nocturnal NIV and sleeping (M). All patients used Volume-Assisted Pressure Control mode (VAPC) at night via a Covidien Puritan Bennett PB560 ventilator (Covidien, Mansfield, USA).

Exclusion criteria comprised patients with ineffective NIV during sleep as assessed by the measurement of TcCO2>49mmHg (S), patients with uncontrollable oral leaks with MPV or episode of acute respiratory infection during the trials. The current study was approved by the local ethics committee and registered (N° registered study. Clinical trial.org follows). The patients gave their written informed consent before study inclusion.

Study design

The study design consisted in a randomized cross-over study. Patients served as their own control. Measurements were made during a 48-hour hospitalization that is scheduled every 6 months in patients attending our Centre for Home Mechanical Ventilation. Hospitalization systematically included nocturnal recordings of transcutaneous carbon dioxide tension (TcCO2) and pulse oximetry (SpO2). Randomized trials were decided by toss and tested during a 1-hour session of assisted breathing via MPV on two separate days. Patients were seated in their wheelchair and trials started with connecting patients to transcutaneous TcCO2 and SpO2 measurements.

Equipment for MPV

Two different MPV equipment sets were compared (figure 1). Each set included separate ventilators, tubing supports and mouthpieces. Both ventilators used volume assisted control mode (VAC) according to the patient preference reported in a previous study (Q).

The first set consisted in a non-dedicated (NON-DED) ventilator for MPV (PB560) using a single active tubing with an exhalation valve. The trigger was set on high sensitivity. Solutions to avoid nuisance from disconnection alarms were used according to a report from Boitano and colleagues (O). The PB560 was combined with a local custom-made tubing support in thermo-formable plastic U-piece placed on the patient shoulders (figure 1 A) described in a previous report (M). The mouthpiece consisted in a 22mm white angled hard plastic mouthpiece (Philips Respironics; Murrysville, USA). Despite being a non MPV-dedicated set, the NON-DED set was previously reported as safe and an effective (M).

The second set included an MPV-dedicated (DED) ventilator (Trilogy 100, Philips Respironics; Murrysville, USA) with an MPV dedicated software with disconnection alarms switched off. This set included a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger. The kiss trigger consisted in a sensitive flow detection system allowing on-demand ventilation via a constant airflow produced by the ventilator. When this constant flow was disrupted by the engagement and disengagement of the patient's lips from the mouthpiece, a single inspiratory cycle was triggered. Finally, the DED equipment included a smart flexible tube support system attached via a wedge on the patient's wheelchair (figure 1 B). The tubing ended with a silicone made mouthpiece designed as a straw. The backup rate in de DED equipment was copied from nighttime values. Similar VAC mode, tidal volumes and inspiratory times were used in both equipment's to facilitate further comparison. Trials were a succession of intermittent disconnections-reconnections to the mouthpiece. All patients were encouraged to manage leaks around the mouthpiece according to their breathing comfort.

Measurements

Day 1

Forced vital capacity (FVC), maximal inspiratory (MIP) and expiratory pressures (MEP) were measured on the first day in seated position as per ATS/ERS guidelines (T) via a heated Fleisch no. 2 pneumotachometer (Metabo, Lausanne, Switzerland). The Borg dyspnea scale on 10 points reflecting the degree of comfortable breathing was also recorded on the first day (C). Other daytime baseline measurements such as transcutaneous oxygen saturation (SpO2) and carbon dioxide tension (TcCO2) were recorded without daytime ventilation via an ear clip connected to a Sentec monitoring (SenTec AG, Therwil, Swizerland). This technique was validated for continuous monitoring of PaCO2 during sleep in this group of patients (U). The participants were asked to determine their free time defined as the time of comfortable spontaneous breathing without NIV. Finally, the maximal active mouth opening (space between upper and lower teeth) was measured.

Day 2 and 3

The maximal TcCO2 and minimal SpO2 values obtained during the trials were measured. As in day 1, the Borg dyspnea score was recorded to evaluate the breathing comfort during MPV trials. A 17-items list assessing the patient perception with a Likert scale ranging from 0 to 5 (0: maximal dissatisfaction, 5: maximal satisfaction) was completed during the trials.

Being tested
Ventilator
Keywords
noninvasive ventilation
Medical subject headings
Neuromuscular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VentilatorDevice

    Comparison of two ventilators for mouthpiece ventilation

Study groups in NCT03867721
Study groupRoleWhat they receive
Ventilator PB560 (Covidien)ExperimentalThe non-dedicated (NON-DED) set comprised a ventilator for MPV (PB560) using a single active tubing with an exhalation valve. A custom-made arm support and plastic mouthpiece were used.
Receives: Device: Ventilator
Ventilator Trilogy (Philips Respironics)ExperimentalThe dedicated (DED) set comprised a ventilator for MPV (Trilogy 100, Philips Respironics; with dedicated software, with a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger, with a smart flexible tube support system and with a silicone made mouthpiece designed as a straw.
Receives: Device: Ventilator

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Transcutaneous Carbon dioxyde

    Maximal level of CO2 tension in blood (PCO2)

    Measured: Day 2: continuous recording during trial 1 (30min)

  2. Transcutaneous Carbon dioxyde

    Maximal level of CO2 tension in blood (PCO2)

    Measured: Day 3: continuous recording during trial 2 (30min)

  3. Trancutaneous Oxygen saturation

    Minimal level of Oxygen saturation (SpO2)

    Measured: Day 2: continuous recording during trial 1 (30min)

  4. Trancutaneous Oxygen saturation

    Minimal level of Oxygen saturation (SpO2)

    Measured: Day 3: continuous recording during trial 2 (30min)

  5. Borg dyspnea score

    Score (0-10 points; 0: very comfortable; 10: very uncomfortable) to evaluate the subjective feeling of breathing comfort. Borg is not an abbreviation but it is name of the author who validated the score. Dyspnea score is named "Borg" visual analogic score

    Measured: Day 2: at the end of trial 1

  6. Borg dyspnea score

    Score (0-10 points; 0: very comfortable; 10: very uncomfortable) to evaluate the subjective feeling of breathing comfort. Borg is not an abbreviation but it is name of the author who validated the score. Dyspnea score is named "Borg" visual analogic score

    Measured: Day 3: at the end of trial 2

  7. A 17-item questionnaire assessing the patient perception

    Score (0-5 points; 0: very bad ; 10: very good ) to evaluate the subjective perception (easiness-comfort) of patients with the ventilator equipment.

    Measured: Day 2: at the end of trial 1

  8. A 17-item questionnaire assessing the patient perception

    Score (0-5 points; 0: very bad ; 10: very good ) to evaluate the subjective perception (easiness-comfort) of patients with the ventilator equipment.

    Measured: Day 3: at the end of trial 2

Secondary outcomes (1)
  1. Freetime

    Time of comfortable spontaneous breathing without assisted ventilation

    Measured: On day 1 (baseline)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Mar 2019
  2. Study start1 Jan 2015
  3. Primary completion30 Dec 2018
  4. Study completion30 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03867721
Sponsor's protocol ID
2014-WMT-001
Status last verified
Mar 2019
First submitted
3 Mar 2019
Last updated
12 Mar 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Ventilator in people with Neuromuscular Diseases, run by Revalidatieziekenhuis InkendaaI at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Transcutaneous Carbon dioxyde (time frame: Day 2: continuous recording during trial 1 (30min)). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2019; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in